BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 11285996)

  • 1. Treatment of osteoporosis with bisphosphonates.
    Watts NB
    Rheum Dis Clin North Am; 2001 Feb; 27(1):197-214. PubMed ID: 11285996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate therapy.
    Licata AA
    Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate treatment of osteoporosis.
    Watts NB
    Clin Geriatr Med; 2003 May; 19(2):395-414. PubMed ID: 12916293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates and osteoporosis treatment in Italy.
    Gennari C; Reginster JY
    Aging (Milano); 1998 Aug; 10(4):284-94. PubMed ID: 9825019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
    Beauchesne MF; Miller PF
    Ann Pharmacother; 1999 May; 33(5):587-99. PubMed ID: 10369624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
    Katayama K; Matsuno T
    Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates for osteoporosis.
    Drug Ther Bull; 2001 Sep; 39(9):68-72. PubMed ID: 11586803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
    Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
    Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
    Curković B
    Reumatizam; 2003; 50(2):49-50. PubMed ID: 15098377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
    Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
    Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term experience with alendronate in the treatment of osteoporosis.
    Hochberg MC; Rizzoli R
    Expert Opin Pharmacother; 2006 Jun; 7(9):1201-10. PubMed ID: 16732706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic prevention of osteoporotic fractures.
    Zizic TM
    Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
    Iwamoto J; Takeda T; Sato Y
    Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD; Delmas PD
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.